Advances in Genitourinary Cancer: Biomarkers, Immunotherapy and Novel Therapeutics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 89
Special Issue Editor
Special Issue Information
Dear Colleagues,
Genitourinary (GU) cancers, including prostate, bladder, kidney, and testicular cancers, represent a diverse group of malignancies with distinct biological behaviors and treatment challenges. Over the past decade, advances in molecular profiling, targeted therapies, and immunotherapy have significantly improved clinical outcomes. Despite these advancements, challenges such as treatment resistance, patient selection for novel therapies, and optimizing therapeutic sequencing remain critical areas of ongoing research. Identifying predictive biomarkers, understanding mechanisms of resistance, and integrating innovative therapeutic approaches are essential for improving patient outcomes.
We are pleased to invite you to contribute to this Special Issue, which will focus on recent developments in the biology, biomarkers, and novel treatment strategies for GU cancers.
This Special Issue aims to provide a comprehensive overview of innovative research in GU cancers, with a focus on molecular and translational advancements that have the potential to impact clinical care. We seek to highlight innovative studies on predictive and prognostic biomarkers, drug resistance mechanisms, and novel therapeutic approaches, including immunotherapy, targeted therapy, and combination strategies. The scope of this Special Issue aligns with the journal’s focus on advancing cancer research and treatment through novel discoveries and translational applications.
In this Special Issue, we welcome original research articles, systematic reviews, and meta-analyses covering a wide range of topics, including but not limited to the following research areas:
- Predictive and prognostic biomarkers in GU cancers;
- Mechanisms of resistance to immunotherapy and targeted therapy;
- Emerging therapeutic strategies, including small molecules, antibody–drug conjugates, and combination therapies;
- Role of circulating tumor DNA (ctDNA) and liquid biopsy in GU cancer management;
- Tumor microenvironment and immune modulation in GU malignancies;
- Real-world evidence and clinical outcomes of novel treatments.
I look forward to your contributions to this Special Issue, which will help advance our understanding of GU cancer biology and treatment strategies.
Dr. Lingbin Meng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genitourinary cancer
- biomarkers
- immunotherapy
- targeted therapy
- chemotherapy
- drug resistance
- tumor microenvironment
- liquid biopsy
- ctDNA
- precision oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
